1. Home
  2. PZG vs SAVA Comparison

PZG vs SAVA Comparison

Compare PZG & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Paramount Gold Nevada Corp.

PZG

Paramount Gold Nevada Corp.

HOLD

Current Price

$2.01

Market Cap

97.2M

ML Signal

HOLD

Logo Cassava Sciences Inc.

SAVA

Cassava Sciences Inc.

HOLD

Current Price

$1.91

Market Cap

96.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PZG
SAVA
Founded
1992
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
97.2M
96.1M
IPO Year
1999
N/A

Fundamental Metrics

Financial Performance
Metric
PZG
SAVA
Price
$2.01
$1.91
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$5.00
AVG Volume (30 Days)
1.9M
812.0K
Earning Date
02-13-2026
03-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.32
$1.15
52 Week High
$2.47
$4.98

Technical Indicators

Market Signals
Indicator
PZG
SAVA
Relative Strength Index (RSI) 77.32 37.63
Support Level $1.54 $2.00
Resistance Level $2.47 $2.15
Average True Range (ATR) 0.22 0.12
MACD 0.04 0.01
Stochastic Oscillator 59.91 5.62

Price Performance

Historical Comparison
PZG
SAVA

About PZG Paramount Gold Nevada Corp.

Paramount Gold Nevada Corp is an exploration-stage mining company. Together with its subsidiaries, the company is engaged in the business of acquiring, exploring, and developing precious metal projects in the United States. Also, it explores for gold and silver. The company enhances the value of projects by implementing exploration and engineering programs that are likely to expand and upgrade known mineralized material to reserves. Its projects include sleeper gold, grassy mountain gold, frost project, other non-material, and others.

About SAVA Cassava Sciences Inc.

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.

Share on Social Networks: